儿童银屑病与共病发生的关联研究
这项回顾性队列研究基于Optum Labs数据库,纳入29957例银屑病患儿与29957例年龄、性别、种族匹配的无银屑病儿童,比较共病发生风险。结果显示银屑病患儿各共病风险显著升高,非肥胖银屑病患儿风险仍升高40%至75%,但肥胖是更强的共病危险因素。
要点
- 银屑病患儿发生肥胖、高脂血症、高血压、糖尿病、代谢综合征、多囊卵巢综合征、非酒精性肝病及肝酶升高的风险均高于无银屑病儿童。
- 非肥胖银屑病患儿相比非肥胖无银屑病儿童,各共病风险升高40%至75%。
- 肥胖是各共病发生的强危险因素,其贡献大于银屑病本身。
核心结论
- 银屑病患儿发生肥胖、高脂血症、高血压、糖尿病、代谢综合征、多囊卵巢综合征、非酒精性肝病及肝功能肝酶升高的风险高于无银屑病儿童。
- 银屑病是这些共病发生的小幅独立危险因素,但肥胖对银屑病患儿共病发生的贡献更大。
研究设计与样本
- 回顾性队列研究,使用Optum Laboratories Data Warehouse理赔数据(包含1.5亿私人保险及Medicare参保者)。
- 纳入29957例银屑病患儿及29957例年龄、性别、种族匹配的无银屑病儿童,分为非肥胖无银屑病(参照队列)、非肥胖银屑病、肥胖无银屑病、肥胖银屑病4组。
- 队列总体平均(SD)年龄为12.0(4.4)岁,女孩16034例(53.5%)。
主要发现
- 基线时银屑病患儿中肥胖者更多(862例[2.9%] vs 463例[1.5%];所有比较P < .001)。
- 银屑病患儿发生每种共病的可能性均显著高于无银屑病儿童(P < .01)。
- 肥胖是每种共病发生的强危险因素,即使在无银屑病者中亦然(风险比[HR]范围为2.26至18.11)。
- 非肥胖银屑病患儿相比非肥胖无银屑病儿童,共病风险升高40%至75%:血脂升高(HR,1.42;95% CI,1.25-1.62)、高血压(HR,1.64;95% CI,1.40-1.93)、糖尿病(HR,1.58;95% CI,1.27-1.95)、代谢综合征(HR,1.62;95% CI,1.13-2.33)、多囊卵巢综合征(HR,1.49;95% CI,1.18-1.88)、非酒精性肝病(HR,1.76;95% CI,1.16-2.65)、肝酶升高(HR,1.46;95% CI,1.27-1.67)。
- 除高血压(P = .03)外,银屑病与肥胖对共病风险无显著交互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Children with psoriasis are at increased risk for comorbidities. Many children with psoriasis are also overweight or obese; it is unknown whether the increased risk of comorbidities in these children is independent of obesity. OBJECTIVE: To determine the risk of elevated lipid levels (hyperlipidemia/hypertriglyceridemia), hypertension, metabolic syndrome, polycystic ovarian syndrome, diabetes, nonalcoholic liver disease, and elevated liver enzyme levels in children with and without psoriasis, after accounting for obesity. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study of claims data from Optum Laboratories Data Warehouse (includes 150 million privately insured and Medicare enrollees). A cohort of 29 957 children with psoriasis (affected children) and an age-, sex-, and race-matched comparator cohort of 29 957 children without psoriasis were identified and divided into 4 groups: (1) nonobese, without psoriasis (reference cohort); (2) nonobese, with psoriasis; (3) obese, without psoriasis; and (4) obese, with psoriasis. MAIN OUTCOMES AND MEASURES: Risk of developing comorbidities (Cox proportional hazards regression). RESULTS: The overall mean (SD) age of those included in the cohort was 12.0 (4.4) years, and 16 034 (53.5%) were girls. At baseline, more affected children were obese (862 [2.9%] vs 463 [1.5%]; P < .001 for all comparisons). Children with psoriasis were significantly more likely to develop each of the comorbidities than those without psoriasis (P < .01). Obesity was a strong risk factor for development of each comorbidity, even in those without psoriasis (hazard ratios [HRs] ranging from 2.26 to 18.11). The risk of comorbidities was 40% to 75% higher among nonobese children with vs without psoriasis: elevated lipid levels (HR, 1.42; 95% CI, 1.25-1.62), hypertension (HR, 1.64; 95% CI, 1.40-1.93), diabetes (HR, 1.58; 95% CI, 1.27-1.95), metabolic syndrome (HR, 1.62; 95% CI, 1.13-2.33), polycystic ovarian syndrome (HR, 1.49; 95% CI, 1.18-1.88), nonalcoholic liver disease (HR, 1.76; 95% CI, 1.16-2.65), and elevated liver enzyme levels (HR, 1.46; 95% CI, 1.27-1.67). Except for hypertension (P = .03), no significant interaction occurred between psoriasis and obesity on the risk of comorbidities. CONCLUSIONS AND RELEVANCE: Children with psoriasis are at greater risk of developing obesity, hyperlipidemia, hypertension, diabetes, metabolic syndrome, polycystic ovarian syndrome, nonalcoholic liver disease, and elevated liver function enzyme levels than children without psoriasis. While psoriasis is a small independent risk factor for the development of these comorbidities, obesity is a much stronger contributor to comorbidity development in children with psoriasis.
引用
- Tollefson MM, Van Houten HK, Asante D, et al. Association of Psoriasis With Comorbidity Development in Children With Psoriasis. JAMA Dermatol. 2018. PMID: 29322175. doi:10.1001/jamadermatol.2017.5417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。